Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study

PLoS Medicine

Volumn 14, Issue 2, 2017, Pages

  Cox, Helen ^a   Dickson Hall, Lindy ^a   Ndjeka, Norbert ^b   van’t Hoog, Anja ^c,d   Grant, Alison ^e,f,g   Cobelens, Frank ^c,d   Stevens, Wendy ^h   Nicol, Mark ^a,h  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^h NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESISTANT TUBERCULOSIS; EVALUATION AND FOLLOW UP; FEMALE; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RESEARCH; RETROSPECTIVE STUDY; ANTIBIOTIC RESISTANCE; CLINICAL PROTOCOL; MULTIDRUG RESISTANT TUBERCULOSIS; SOUTH AFRICA;

ADULT; ANTIBIOTICS, ANTITUBERCULAR; CLINICAL PROTOCOLS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85014500992     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002238     Document Type: Article

References (19)

1. World Health OrganizationGlobal tuberculosis report 2015. WHO/HTM/TB/2015.22. Geneva: World Health Organization; 2015.
2. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE, Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A. 2008;105(32):11293–8. doi: 10.1073/pnas.080096510518695217
3. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495–505. doi: 10.1016/S0140-6736(11)60438-821507477
4. Harris RC, Grandjean L, Martin LJ, Miller AJ, Nkang JE, Allen V, et al. The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review. BMC Infect Dis. 2016;16(1):193.
5. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA, Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012;9(11):e1001347. doi: 10.1371/journal.pmed.100134723185139
6. Cox H, Dickson-Hall L, Ndjeka N, van’t Hoog A, Grant AD, Cobelens F, et al. Data from: Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: a retrospective cohort study. Dryad Digital Repository.
7. South African National AIDS CouncilNational strategic plan (NSP) for HIV and AIDS, TB and STIs 2012–2016. Pretoria: South African National AIDS Council; 2013.
8. Cox H, Mbhele S, Mohess N, Whitelaw A, Muller O, Zemanay W, et al. Impact of Xpert MTB/RIF implementation for TB diagnosis in a high TB and HIV prevalence primary care clinic in South Africa: a pragmatic randomised trial. PLoS Med. 2014;11(11):e1001760. doi: 10.1371/journal.pmed.100176025423041
9. Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health. 2015;3(8):e450–7. doi: 10.1016/S2214-109X(15)00100-X26187490
10. Van Den Handel T, Hampton KH, Sanne I, Stevens W, Crous R, Van Rie A, The impact of Xpert((R)) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015;19(4):392–8. doi: 10.5588/ijtld.14.065325859993
11. World Health OrganizationGlobal tuberculosis control: WHO report 2012. Geneva: World Health Organization; 2012.
12. South African National Department of HealthManagement of drug-resistant tuberculosis: policy guidelines. Pretoria: South African National Department of Health; 2011.
13. Naidoo P, du Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A, et al. A comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert(R) MTB/RIF-based algorithms in a routine operational setting in Cape Town. PLoS ONE. 2014;9(7):e103328. doi: 10.1371/journal.pone.010332825079599
14. Cox H, Daniels J, Muller O, Nicol M, Cox V, Van Cutsem G, et al. Impact of decentralized care and the Xpert MTB/RIF test on rifampicin-resistant tuberculosis treatment initiation in Khayelitsha, South Africa. Open Forum Infect Dis. 2015;2(1):ofv014. doi: 10.1093/ofid/ofv01426034764
15. South African National Department of HealthWorld Health OrganizationTowards universal health coverage: report of the evaluation of South Africa drug resistant TB programme and its implementation of the policy framework on decentralised and deinstitutionalised management of multidrug resistant TB. Pretoria: South African National Department of Health; 2016.
16. Loveday M, Wallengren K, Voce A, Margot B, Reddy T, Master I, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2012;16(2):209–15. doi: 10.5588/ijtld.11.040122236922
17. Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012;16(1):90–7. doi: 10.5588/ijtld.11.015322236852
18. Dodd PJ, Sismanidis C, Seddon JA, Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16(10):1193–201. doi: 10.1016/S1473-3099(16)30132-327342768
19. Dreyer A, Omar S, Nanoo A, Koornhof H, Ismail N, Public health action to reduce the burden of rifampicin resistant tuberculosis. Communicable Dis Surveill Bull. 2015;13(2):47–51. Johannesburg: National Institute for Infectious Diseases.